CS
CSPC Pharmaceutical Group Limited
CSPCY · OTC
$4.72 +5.12% (+$0.23)
1M -5.22%
Market Cap ¥90.9B
P/E Ratio 24.09x
Div. Yield 3.15%
ROE 11.08%
Bulios Fair Price
$2.68
43.2% downside
Current Price
$4.72
Undervalued Fair Value Overvalued
According to Bulios Fair Price, CSPCY is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Moderate
6/9Valuation
49 /100
Fair P/E 24.09x
P/FCF 25.61x
EV/EBITDA 16.34x
Growth
4 /100
Declining EPS growth 13.51%
Book val. growth 3.69%
Rev. growth 6.50%
Profitability
82 /100
Strong Gross margin 65.59%
FCF margin 14.04%
Net margin 14.93%
Quality
52 /100
Average ROIC 8.42%
Asset turnover 0.54x
ROE 11.08%
Debt
100 /100
Low Debt/Equity 0.02x
Net debt/EBITDA -1.04x
Current ratio 2.19x
Stability
91 /100
Stable Beta 0.75x
Profitable years 6
Rev. volatility 15.30%
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about CSPCY
Online
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Lei Cai
Employees
19,700
Headquarters
Shijiazhuang
Upcoming events
21 OCT
Ex-Dividend
Ex-dividend date
25 NOV
Dividend Payment
Payment date